Syndax制药 SNDX 深 沪
等待开盘 01-28 09:30:00 美东时间
21.31
-0.090
-0.42%
华盛通- 最 高21.495
- 今 开21.16
- 成交量 69.72万股
- 最 低 20.66
- 昨 收 21.40
- 总市值 18.36亿
- 52周最高 22.73
- 市盈率 静 --
- 换手率 0.81%
- 52周最低 8.58
- 委 比 48.84%
- 总股本 8614.19万
- 历史最高 29.86
- 量 比 0.49
- 振 幅 3.90%
- 历史最低 3.39
- 每 手 1
- 风险率 3.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
今天 10:59
Mizuho Maintains Outperform on Syndax Pharmaceuticals, Raises Price Target to $600
Mizuho analyst Mara Goldstein maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Outperform and raises the price target from $410 to $600.
今天 00:03
Syndax Pharma And World Orphan Drug Alliance Collaborate To Expand Access To Menin Inhibitor, Revuforj, Through Managed Access Program
- Program will expand access in certain regions where Revuforj is not available commercially, as permitted by local regulations -- Program will be launched in parts of Eurasia, Central and Southeast Europe, Israel, the
01-07 20:12
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
Syndax Pharmaceuticals and the World Orphan Drug Alliance (WODA) have partnered to expand access to Revuforj, a menin inhibitor, through a Managed Access Program in regions where it is not commercially available but permitted by local regulations. The program will launch in parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa. Revuforj is FDA approved for treating relapsed or refractory acute ...
01-07 12:00
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
Syndax Pharmaceuticals' CEO, Michael A. Metzger, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will be live-streamed and archived on the company's website. Syndax, a leader in cancer therapies, focuses on innovative treatments including FDA-approved Revuforj® and Niktimvo™, and is advancing multiple clinical trials.
01-05 12:00
Syndax Pharmaceuticals Modernizes Bylaws for Electronic Share Issuance
Syndax Pharmaceuticals ( ($SNDX) ) has provided an announcement. On December 18...
2025-12-20 06:09
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
Syndax Pharmaceuticals' Revuforj® (revumenib), a first-in-class menin inhibitor, was awarded "Best New Drug" at the 2025 Scrip Awards, recognizing its groundbreaking science and therapeutic advances in treating relapsed or refractory acute leukemias with specific genetic mutations. Revuforj, approved for two patient populations in 2024 and 2025, received the award alongside its recent expanded approval for acute myeloid leukemia (AML) with NPM1 m...
2025-12-12 12:00
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
BTIG Reiterates Buy on Syndax Pharmaceuticals, Maintains $56 Price Target
BTIG analyst Justin Zelin reiterates Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and maintains $56 price target.
2025-12-09 21:03
Syndax Pharma Highlights Key Revuforj Presentations Spanning Acute Leukemia Treatment Continuum Presented At ASH Annual Meeting
– First real-world evidence for a menin inhibitor shows 77% ORR (10/13), 31% (4/13) CR/CRh, 75% (9/12) MRD negativity, and favorable tolerability among primarily R/R NPM1m, KMT2Ar, and NUP98r acute leukemia pts ––
2025-12-08 19:52
